Ichnos Glenmark Innovation (IGI), a collaboration between Ichnos Sciences Inc. and Glenmark Pharmaceuticals Ltd., announced that it will present first-time data from its Phase 1 study of ISB 2001 at the 66th American Society of Hematology (ASH) Annual Meeting in San Diego, California. ISB 2001 is IGI’s first-in-class tri-specific antibody, designed to target BCMA and …